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ABSTRACT
A non–total body irradiation–containing preparative regimen was studied in young children (<4 years old)
undergoing unrelated donor cord blood transplantation as part of the Cord Blood Transplantation trial for the
treatment of acute lymphoblastic leukemia (n  14), acute myeloid leukemia (n  13), undifferentiated
leukemia (n  1), juvenile myelomonocytic leukemia (n  2), and myelodysplastic syndromes (n  2).
Donor/recipient HLA matching based on low-/intermediate-resolution molecular typing for HLA-A and -B
and high-resolution HLA-DRB1 typing was 5/6 or 6/6 (n  21) or 4/6 (n  11). The preparative therapy
consisted of busulfan, melphalan, and antithymocyte globulin, with cyclosporine and corticosteroids for
graft-versus-host disease (GVHD) prophylaxis. The median age was 1.6 years (range, 0.5-3.9 years), and the
median weight was 10.5 kg (range, 5.8-19.5 kg). Cord blood grafts contained a median of 10.7  107 nucleated
cells per kilogram (range, 4.6-29.2) and 2.6  105 CD34 cells per kilogram (range, 0.7-8.3). The cumulative
incidence (CINC) of neutrophil recovery (absolute neutrophil count >500/L) at day 42 was 0.59 (95%
confidence interval [CI], 0.44-0.78) at a median of 31 days (range, 23-55 days). The CINC and Kaplan-Meier
estimates of platelet engraftment at day 180 were 0.53 (95% CI, 0.34-0.69) and 0.82 (95% CI, 0.61-1.00),
respectively. CINC estimates of grade III/IV acute GVHD at day 100 and chronic GVHD at 1 year were 0.25
(95% CI, 0.09-0.41) and 0.26 (95% CI, 0.09-0.44), respectively. The CINC estimate of relapse was 0.31 (95%
CI, 0.16-0.47) at 2 years. With a median follow-up of 27.8 months (range, 23.4-46.7 months), the probability
of survival at 1 year was 0.47 (95% CI, 0.30-0.64). A preparative regimen containing a busulfan/melphalan/
antithymocyte globulin preparative regimen is well tolerated in the setting of unrelated donor cord blood
transplantation for childhood leukemia and can serve as a platform preparative regimen for intensifying host
immunosuppression and antileukemic therapy to allow for improved engraftment and improved relapse-free
survival.
© 2005 American Society for Blood and Marrow Transplantation
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6NTRODUCTION
Unrelated donor cord blood transplantation (CBT)
s an evolving treatment option for a variety of hema-
ologic, immunologic, and metabolic diseases [1]. The
ational Heart, Lung and Blood Institute–sponsored
hase II Cord Blood Transplantation (COBLT) study
as a multicenter study designed to determine
hether cord blood is a suitable source of hematopoi-
tic stem cells for children and adults with hemato-
ogic malignancies, immune deﬁciency disorders, or
nborn errors of metabolism.
Although allogeneic transplantation offers poten-
ially curative therapy to children and adults with
therwise untreatable malignancies, only a fraction of
atients will have an HLA-matched donor in their
amily. Networks of unrelated volunteer donors have
een established to provide an alternative donor
ource for those without family donors [2]. However,
ith current HLA matching requirements, there re-
ain a large proportion of patients for whom an
nrelated volunteer donor is not identiﬁed in a timely
ashion. This is especially true for recipients not of
orthern European descent and children with leuke-
ia. Allogeneic transplantation from unrelated mar-
ow donors is more frequently complicated by severe
raft-versus-host disease (GVHD) or graft rejection
3,4]. Most prior studies with CBT have focused on
otal body irradiation (TBI)–based preparative regi-
ens. There was interest in evaluating a non-TBI
egimen for patients unable to tolerate TBI because of
retransplantation toxicity and leukemia patients 4
ears of age. However, there was concern about
hether a non–TBI-based regimen would be sufﬁ-
iently immunosuppressive to allow engraftment in
he setting of CBT [5-8]. TBI has been shown to be
uperior to busulfan and cyclophosphamide in trials of
cute lymphoblastic leukemia (ALL); thus, an alterna-
ive non-TBI preparative regimen was sought [9-11].
One stratum of the COBLT trial was to investi-
ate the safety and efﬁcacy of busulfan, melphalan,
nd antithymocyte globulin (ATG) as an alternative
onditioning regimen to TBI. The results of the pe-
iatric leukemia patients 4 years old presented in
his article also allow for analysis of CBT outcome in
cohort of leukemia patients in whom the cord blood
ucleated cell dose was not limiting.
ATERIALS AND METHODS
tudy Design
The COBLT trial was initiated in 1996 and in-
luded 8 strata. One stratum was designed to evaluate
he toxicity and efﬁcacy of busulfan/melphalan/ATG
nd CBT. The ﬁrst 2 years of the COBLT project
ocused on establishing 3 cord blood banks for pa-
ients searching for an unrelated donor CBT. Stan- s
38ard operating procedures for the cord blood banks
ere written and applied [12]. While cord blood units
CBUs) were being collected, HLA typing methods
nd a search algorithm were developed. The trans-
lantation protocol and manual of procedures were
lso developed for the transplant centers. Search ac-
ivity was initiated in November 1998. The ﬁrst pa-
ient was enrolled in January 1999.
For each stratum, the primary end point for the
tudy was survival at 180 days after transplantation.
he secondary end points included engraftment (my-
loid and platelet), incidence of acute and chronic
VHD, relapse-free survival, overall survival, inci-
ence of relapse, and incidence of nonrelapse morbid-
ty and mortality.
atients
The transplantation protocol was approved at the
nstitutional review board of each of the 26 participat-
ng institutions. Consent was obtained for all patients
rom their legal guardian before enrollment and treat-
ent.
Thirty-eight patients with leukemia or myelodys-
lastic syndrome (MDS) were enrolled from January
999 to May 2002. Eligibility for this treatment stra-
um included (1) age2 years at diagnosis of leukemia
resulting in an age 4 years at transplantation), (2)
nability to tolerate TBI because of prior radiation
herapy or organ toxicity, or (3) refractory/multiply
ecurrent leukemia for which a traditional TBI/cyclo-
hosphamide regimen historically carried a low like-
ihood of successful outcome. This article presents the
utcome of transplantations in the 32 children 4
ears old who were enrolled on this trial. Within that
ubset, infant leukemia was deﬁned as all cases diag-
osed as leukemia before 6 months of age or diag-
osed before 12 months of age with cytogenetic rear-
angements carrying the mixed lineage leukemia gene.
Patients with active central nervous system dis-
ase, human immunodeﬁciency virus seropositivity,
ansky performance score 50%, primary myeloﬁ-
rosis, or suitable related donors were ineligible. Pa-
ients with prior allogeneic stem cell transplantation
ithin 12 months or autologous transplantation
ithin 6 months were excluded, as were individuals
ith uncontrolled bacterial, viral, or fungal infections.
ultiorgan assessment performed before enrollment
as required to demonstrate the following: serum
reatinine normal for age or a creatinine clearance
50% of the lower limits of normal for age; aspartate
minotransferase 5 times the upper limit of normal
nd total serum bilirubin 2.5 mg/dL; asymptomatic
ardiac status or left ventricular ejection fraction
40% that improved with exercise; and asymptomatic
ulmonary function or forced expiratory volume in 1
econd and diffusion capacity 45% of predicted
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Busulfan/Melphalan Preparative Regimen for Cord Blood Transplantation
Bcorrected for hemoglobin). The selected CBU was
equired to provide a minimum of 1  107 total
ucleated cells (before cryopreservation) per kilogram
f recipient weight. Patients were characterized as
igh risk if they had disease features that were histor-
cally associated with poor transplantation outcomes:
nfant leukemia; ALL in second complete remission
CR2) with length of CR118 months; acute myeloid
eukemia (AML) associated with monosomy 7, tri-
omy 8, or prior MDS; therapy-related AML; ALL or
ML in CR3 or relapse; juvenile myelomonocytic
eukemia in any stage of disease; and MDS.
onor Selection
For study enrollment, the donor/recipient HLA
atch was determined by low-/intermediate-resolu-
ion molecular typing for class I HLA-A and -B alleles
nd high-resolution molecular typing for HLA-DRB1
lleles (original HLA match). Retrospective high-res-
lution molecular typing for HLA-A, -B, and -DRB1
lleles was performed (ﬁnal HLA match).
Eligibility criteria required the availability of a
ryopreserved CBU with a minimum 4/6 HLA match
r a 3/6 HLA-matched unit provided that the 3 HLA
oci were all typed by high-resolution molecular typ-
ng and there was at least 1 match for the HLA-A, -B,
nd -DRB1 loci. Only patients receiving 1 cord unit
ere eligible. Initially, the COBLT study required
hat CBUs had to be obtained from the COBLT cord
lood banks. This criterion was subsequently ex-
anded to allow units obtained from the New York
lood Center, National Marrow Donor Program–
pproved cord blood banks, or US banks meeting
ETCORD-FACT standards.
reatment Plan
All patients received busulfan every 6 hours for 16
oses on day8 through day5 either orally (n 21)
r intravenously (IV; n  11). Oral busulfan was
dministered at 20 mg/m2 (age 3 months), 40
g/m2 (age 3 months to 6 years), or 1 mg/kg (age 6
ears); IV busulfan was administered at 1 mg/kg (age
4 years) or 0.8 mg/kg (age4 years). Busulfan doses
ere adjusted to a achieve a targeted concentration
teady state of 600 to 900 ng/mL. Melphalan (45
g/m2/d) was given on days 4, 3, and 2. Equine
TG (30 mg/kg/d) was given on days 3, 2, and
1. On the day of transplantation, patients received 2
oses of methylprednisolone 1 mg/kg, with 1 dose
iven just before the CBU infusion (day 0). GVHD
rophylaxis consisted of methylprednisolone 0.5
g/kg twice daily on day 1 through 4 and then 1
g/kg twice daily from day5 to day19 or until the
rst day the absolute neutrophil count (ANC) reached
00/L, at which time the dose was tapered at the rate
f 0.2 mg/kg/wk. Cyclosporine was begun on day 3
nd continued to at least day 180, when the dose was i
B&MTapered at the rate of 5% per week of the initial dose
f the recipients had no evidence of GVHD. CBUs
ere thawed according to the process developed by
ubinstein et al. [13].
nd Point Definitions
Survival was deﬁned as the time from transplan-
ation to the day of death or the day of last follow-up.
elapse-free survival was deﬁned as the time from
ransplantation to the day of death or relapse or the
ay of last follow-up.
Neutrophil engraftment was deﬁned as achieving
n ANC at least 500/L for 3 consecutive measure-
ents on different days and demonstrated donor chi-
erism 90%. All patients who survived at least 14
ays were considered evaluable. Primary graft failure
as deﬁned as the failure to attain neutrophil engraft-
ent by day 42. Neutrophil hematopoietic recovery
as deﬁned as achieving ANC at least 500/L for 3
onsecutive measurements on different days. Patients
ho died between day 14 and day 42 and had not
chieved neutrophil engraftment were classiﬁed as
aving primary graft failures. Secondary graft failure
as deﬁned as a loss of neutrophil engraftment. Plate-
et engraftment was deﬁned as the ﬁrst day of a min-
mum of 3 consecutive measurements on different
ays such that the patient achieved a platelet count
20 000/L or 50 000/L and was platelet transfu-
ion independent for a minimum of 7 days. The time
o neutrophil or platelet engraftment was deﬁned as
he time from transplantation to the ﬁrst day of en-
raftment.
Acute GVHD assessments were every 7 days to
ay 100 after CBT and then on day 120 and day 150
fter CBT. The grading of acute GVHD followed the
VHD consensus grading scheme [14]. An algorithm
alculated the maximum GVHD clinical grade on the
asis of the weekly organ staging in skin, upper and
ower gastrointestinal tract, and liver. This calculated
rgan stage was decreased by 1 stage if a listed speciﬁc
ifferential diagnosis was reported for either gastro-
ntestinal tract or liver. An independent panel re-
iewed all weekly records and assigned each patient a
nal maximum grade, similar to the methods de-
cribed by Weisdorf et al [15].
Relapse of acute leukemia was diagnosed when
eukemic blasts were documented in the blood or
arrow (25%), when there were 5% blasts and
here were supporting cytogenetic abnormalities, or
hen disease was present at an extramedullary site.
ime to relapse was deﬁned as the time to the ﬁrst
bservation characteristic of relapse.
auses of Morbidity and Mortality
Primary causes of death were reported by follow-
ng the hierarchy developed for the Unrelated Donor
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6arrow Transplantation Trial (http://spitﬁre.emmes.
om/study/tcd/). The hierarchy was developed by an
xpert panel and was based on reﬁnements to the
ational Marrow Donor Program hierarchy for re-
orting causes of death. The hierarchy requires that
raft failure, relapse, or GVHD (if they occur) be
eported as the primary cause of death, rather than
auses such as infection, organ failure, or hemorrhage,
nd also provides rules for reporting secondary causes
f death.
Clinically signiﬁcant infections were reported af-
er transplantation by site of infection, organism, and
everity (moderate required oral antibiotic therapy;
evere required IV antibiotic therapy and was life-
hreatening or fatal). Readmissions after the initial
ischarge for the transplantation were reported by
ate and primary and secondary reasons for admission.
he Bearman toxicity scale [16] was used to report
aximum regimen-related toxicity by day 42 after
ransplantation.
ata Collection
Transplant centers prospectively completed Na-
ional Marrow Donor Program data-collection forms
nd targeted forms for secondary end points and sup-
ortive care. Clinical outcome data were collected
rom the date of transplantation until June 30, 2004, at
hich time the data ﬁle was closed.
tatistical Analysis
Survival estimates were calculated by using the
aplan-Meier (KM) method [17]. Testing for differ-
nces in survival between groups used the log-rank
est. Neutrophil and platelet recoveries, acute and
hronic GVHD, and relapse were analyzed by using
he cause-speciﬁc failure probability method (or cu-
ulative incidence; CINC), where death was treated
s a competing risk [18]. The complement of the KM
stimate for these end points was used to calculate the
umulative probability. Because of the small sample
ize, multivariate modeling methods were not pre-
ented. No imputation was used for any missing data.
requency data in cross-tabulation tables were com-
ared by using the Kruskal-Wallis test. All analyses
ere performed with SAS software version 8.2 (SAS
nstitute Inc, Cary, NC). The analysis is based on
nrolled patients younger than 4 years of age.
ESULTS
tudy Population
Thirty-eight patients were enrolled in this stratum
y 11 transplant centers, and 50% of the patients were
nrolled by 1 center. Six of the 38 patients, aged 8 to 17
ears, were enrolled because of an inability to tolerate
BI. Of these 6, 5 died early after transplantation be-
ause of acute GVHD (n  3), graft failure (n  1), or t
40nterstitial pneumonia (n  1). The remaining 32
hildren with leukemia, younger than 4 years of age at
able 1. Baseline Characteristics
Variable Data
umber of patients 32
ge (y)
Median 1.6
Range 0.5-3.9
eight (kg)
Median 10.5
Range 5.8-19.5
otal nucleated cell dose ( 107/kg)
Median 10.7
Range 4.6-29.2
D34 cell dose ( 105/kg)
Median 2.6
Range 0.7-8.3
D3 cell dose ( 107/kg)
Median 1.6
Range 0.6-3.3
ank, n (%)
COBLT 26 (81)
Other 6 (19)
ecipient sex, n (%)
Male 13 (41)
Female 19 (59)
ecipient ethnicity, n (%)
White 18 (56)
Black 6 (19)
Hispanic 7 (22)
Mixed 1 (3)
onor/recipient ethnicity, n (%)
White/white or other/other 25 (78)
White/other or other/white 7 (22)
rimary disease, n (%)
ALL 14 (44)
AML 13 (41)
JMML 2 (6)
Myelodysplastic syndrome 2 (6)
Undifferentiated leukemia 1 (3)
nfant leukemia, n (%)*
Infant leukemia 19 (59)
Others 13 (41)
isk status, n (%)
Good 2 (6)
Poor† 30 (94)
erformance status, n (%)
90% or 100% 28 (88)
<80% 4 (12)
ecipient CMV status, n (%)
Positive 11 (34)
Negative 20 (66)
ransplant center, n (%)
Duke 16 (50)
Others 16 (50)
MML indicates juvenile myelomonocytic leukemia.
Infant leukemia was deﬁned as all children diagnosed with leuke-
mia 6 months of age or before 12 months of age with cyto-
genetic rearrangements carrying the mixed lineage leukemia
gene.
Infant leukemia; ALL-CR2 with length of CR1 18 months;
AML associated with monosomy 7, trisomy 8, or prior myelo-
dysplastic syndrome; therapy-related AML; ALL or AML in
CR3 or relapse; JMML in any stage of disease; and MDS.ransplantation, are the focus of this analysis. The
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Bedian follow-up time for the 32 patients is 27.8
onths (range, 23.4-46.7 months).
Baseline characteristics are shown in Table 1. The
edian age was 1.6 years (range, 0.5-3.9 years); 56%
ere white, and 59% were female. The primary diag-
osis was ALL (44%), AML (41%), juvenile my-
lomonocytic leukemia (6%), MDS (6%), and undif-
erentiated leukemia (3%). Most (88%) patients had a
ansky score of 90% or 100%, and most (94%) were
poor risk for transplantation as deﬁned in the “Ma-
erials and Methods” section. The median cryopre-
erved cell doses were 10.7  107 total nucleated cells
TNCs) per kilogram (range, 4.6-29.2), 2.6  105
D34 cells per kilogram (range, 0.7-8.3), and 1.6 
07 CD3 cells per kilogram (range, 0.6-3.3).
Results of donor-recipient HLA matching are
hown in Table 2. On the basis of original donor-
ecipient HLA typing, 3 (9%) patients were matched
t 6 of 6 HLA antigens, and 18 (56%) patients were
atched at 5 of 6 and 11 (34%) were matched at 4 of
HLA antigens. Retrospective high-resolution mo-
ecular HLA typing for HLA-A, -B, and -DRB1 was
ompleted for 30 patients, and 2 patients were classi-
ed as matched at 6 of 6 HLA alleles by retrospective
yping. Of the 17 patients originally matched at 5 of 6
LA antigens and retyped at high resolution, 6 were
eclassiﬁed as 4 of 6 and 1 was reclassiﬁed as 3 of 6. Of
he 10 patients originally matched at 4 of 6 HLA
ntigens and retyped at high resolution, 5 were reclas-
iﬁed as 3 of 6 HLA matched. In summary, 13 (43%)
f 30 patients were reclassiﬁed on the basis of high-
esolution HLA typing.
urvival
The primary end point of this study was survival at
80 days after CBT. For the 32 leukemia patients
ounger than 4 years of age at the time of enrollment,
he overall probability of survival was 0.56 (95% con-
dence interval [CI], 0.39-0.73) and 0.47 (95% CI,
.30-0.64) at day 180 and 1 year, respectively (Figure
A). Figure 1B shows survival by pretransplant remis-
ion status. Survival curves by original and ﬁnal HLA
atch are demonstrated in Figures 1C and 1D, re-
pectively. The higher-level HLA match shows im-
roved survival in both curves. However, the differ-
able 2. Original HLA Match by Final HLA Match
Original
HLA Match
Total No.
Patients Enrolled
Total No. Patie
with HR HLA Ty
4/6 11 10
5/6 18 17
6/6 3 3
Total 32 30
ata are n or n (%); percentages are based on the number of patie
R indicates high resolution.
B&MTnce is statistically signiﬁcant only when the ﬁnal
igh-resolution HLA-A, -B, and -DRB1 match is con-
idered (Figure 1D; P  .03).
As shown in Table 3, age, weight, sex, ethnicity,
rimary disease, recipient cytomegalovirus (CMV)
tatus, TNC dose, CD34 dose, CD3 dose, and
ransplantation center did not signiﬁcantly inﬂuence
urvival. Donor/recipient sex match (P  .01) and
igh-resolution HLA match (P  .01) were the only 2
actors that were associated with improved survival.
Twenty-two of the 32 patients died. The most
ommon causes of death were relapse (n  8), graft
ailure (n  4), acute GVHD (n  5), and chronic
VHD (n 3). One death each was attributed to viral
nfection and interstitial pneumonia.
ngraftment
The CINC and KM estimates of neutrophil re-
overy at day 42 are 0.59 (95% CI, 0.44-0.78) and 0.69
95% CI, 0.51-0.87), respectively (Figure 2A). No
actor, including age, weight, sex, ethnicity, primary
isease, HLA match, recipient CMV status, TNC
ose, CD34 dose, or CD3 dose, was associated with
he incidence of neutrophil engraftment. Also, there
as no difference in the occurrence of primary graft
ailure between patients receiving IV versus oral
usulfan (4/11 patients and 6/21 patients, respec-
ively). The median time to engraftment was 31 days
range, 11-55 days). Three additional patients en-
rafted after day 42 (ie, days 49, 53, and 55). Two
atients had ANC recovery but no chimerism testing.
ix patients died without ANC recovery on days 15,
4, 34, 65, 105, and 127. Chimerism was complete in
ll patients tested except for 1, who had 70% donor
ells on the day of last evaluation (death on day 37).
The CINC and KM estimates of platelet engraft-
ent at day 180 are 0.53 (95% CI, 0.34-0.69) and 0.82
95% CI, 0.61-1.00), respectively (Figure 2B). Age,
eight, sex, primary disease, original and ﬁnal HLA
atch, CMV status, TNC dose, CD34 dose, CD3
ose, and transplant center did not signiﬁcantly affect
latelet recovery. Only recipient ethnicity was associ-
ted with the incidence of platelet engraftment: white
ecipients had a higher incidence of platelet engraft-
ent (P  .04).
Final HLA Match
3/6 4/6 5/6 6/6
5 (50) 5 (50) 0 (0) 0 (0)
1 (6) 6 (35) 10 (59) 0 (0)
0 (0) 0 (0) 1 (33) 2 (67)
6 (20) 11 (37) 11 (37) 2 (7)
o were retrospectively typed.nts
ping
nts wh641
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6igure 1. Probability of survival by covariates. A, Overall survival and CINC of relapse. B, Overall survival by remission status. C, Overall
urvival by original HLA match. D, Overall survival by retrospective HLA match.
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Bcute and Chronic GVHD
The CINC and KM estimates for grade II to IV
cute GVHD at day 100 were 0.41 (95% CI, 0.25-
.56) and 0.44 (95% CI, 0.26-0.62). Ten patients had
rades III/IV acute GVHD. The CINC and KM
stimates for grade III/IV acute GVHD at day 100
ere 0.25 (95% CI, 0.09-0.41) and 0.27 (95% CI,
.11-0.44), as shown in Figure 2C. Six patients out of
3 who survived at least 100 days developed chronic
VHD. The CINC and KM estimates for chronic
VHD at 1 year were 0.26 (95% CI, 0.09-0.44) and
.33 (95% CI, 0.11-0.56), as shown in Figure 2D.
egimen-Related Toxicity
Maximum Bearman toxicity across all organ sys-
ems was reported up to day 42 after CBU infusion.
ive patients exhibited severe toxicity (Figure 3), and
able 3. Survival Results
Characteristics n
Survival (95
at Day 1
verall 32 0.56 (0.39-
ge (y)
<1.6 16 0.69 (0.46,
>1.6 16 0.44 (0.19,
eight (kg)
<11 15 0.73 (0.51,
>11 17 0.41 (0.18,
ex
Male 13 0.69 (0.44,
Female 19 0.47 (0.25,
onor/recipient sex
M/M or F/F 14 0.79 (0.57,
M/F or F/M 18 0.39 (0.16,
thnicity
White 18 0.50 (0.27,
Other 14 0.64 (0.39,
rimary disease
Infant leukemia 19 0.68 (0.48,
Other 13 0.38 (0.12,
riginal HLA match
4/6 11 0.55 (0.25,
5/6 or 6/6 21 0.57 (0.36,
inal HLA match
3/6 or 4/6 17 0.35 (0.13,
5/6 or 6/6 13 0.85 (0.65,
ytomegalovirus serostatus
Positive 11 0.45 (0.16,
Negative 21 0.62 (0.41,
otal nucleated cell dose ( 107/kg)
0 to <10.7 16 0.56 (0.32,
>10.7 16 0.56 (0.32,
D34 cell dose ( 105/kg)
0 to <2.6 13 0.46 (0.19,
>2.6 13 0.62 (0.35,
D3 cell dose ( 105/kg)
0 to <156.2 13 0.46 (0.19,
>156.2 13 0.62 (0.35,
ransplant center
Duke 16 0.50 (0.26,
Other 16 0.63 (0.39,
The upper limit of 95% CI in some cases could not be estimated9% had a maximum toxicity of grade I to II. Notably, a
B&MTo patient had severe grade IV mucositis. However, 3
atients were reported to have grade IV cardiac tox-
city.
elapse-Free Survival
Ten patients relapsed: 4 who received IV busulfan
nd 6 who received oral busulfan. The CINC and KM
stimates of leukemia relapse at 2 years were 0.31
95% CI, 0.16-0.47) and 0.46 (95% CI, 0.25-0.68),
espectively, at a median of 200 days (range, 41-464
ays) after CBT (Figure 1A). No difference in the
ncidence of relapse was observed by disease (ALL
ersus AML) or disease status at the time of transplan-
ation (CR1 versusCR2). The KM estimate of relapse-
ree survival at 2 years was 0.28 (95% CI, 0.13-0.44).
elapse was hematologic (n  9) or extramedullary
n  1); no patient had central nervous system relapse
Survival (95% CI)
at 1 y Median (95% CI)* P Value
0.47 (0.30, 0.64) 282 (105, 951)
.58
0.56 (0.32, 0.81) 536 (177, 951)
0.38 (0.14, 0.61) 130 (80-)
.44
0.60 (0.35, 0.85) 545 (189, 951)
0.35 (0.13, 0.58) 127 (73-)
.29
0.54 (0.27, 0.81) 527 (177-)
0.42 (0.20, 0.64) 132 (80, 644)
<.01
0.79 (0.57, 1.00) — (527-)
0.22 (0.03, 0.41) 119 (73, 226)
.85
0.44 (0.21, 0.67) 258 (105-)
0.50 (0.24, 0.76) 377 (37, 951)
.47
0.58 (0.36, 0.80) 527 (177, 951)
0.31 (0.06, 0.56) 105 (65-)
.75
0.45 (0.16, 0.75) 226 (73, 951)
0.48 (0.26, 0.69) 339 (127-)
<.01
0.29 (0.08, 0.51) 106 (36, 398)
0.69 (0.44, 0.94) — (341-)
.25
0.45 (0.16, 0.75) 105 (34, 951)
0.48 (0.26, 0.69) 339 (132-)
.71
0.44 (0.19, 0.68) 208 (80-)
0.50 (0.26, 0.75) 368 (105, 951)
.39
0.38 (0.12, 0.65) 132 (37, 527)
0.54 (0.27, 0.81) 545 (105, 951)
.58
0.38 (0.12, 0.65) 132 (65, 644)
0.54 (0.27, 0.81) 397 (83, 951)
.79
0.44 (0.19, 0.68) 233 (73-)
0.50 (0.26, 0.75) 377 (132, 951)% CI)
80
0.73)
0.91)
0.68)
0.96)
0.65)
0.94)
0.70)
1.00)
0.61)
0.73)
0.89)
0.89)
0.65)
0.84)
0.78)
0.58)
1.00)
0.75)
0.83)
0.81)
0.81)
0.73)
0.88)
0.73)
0.88)
0.75)fter CBT.
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6igure 2. Incidence and probability of neutrophil and platelet engraftment and acute and chronic GVHD. A, Hematopoietic recovery. B,
latelet recovery (50 000/L). C, Acute GVHD grades III/IV. D, Chronic GVHD (limited or extensive).
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Busulfan/Melphalan Preparative Regimen for Cord Blood Transplantation
BISCUSSION
Cryopreserved unrelated CBUs offer an alterna-
ive donor source of hematopoietic stem cells for
oung children with leukemia that necessitates alloge-
eic hematopoietic stem cell transplantation. A pre-
arative regimen of high doses of busulfan, melphalan,
nd ATG was tested as a non–TBI-based cytoreduc-
ive regimen in an attempt to avoid the potential
ong-term neurologic and endocrine complications of
BI in young children [19,20]. In addition to avoiding
he toxicity of TBI, the busulfan and melphalan com-
ination introduces 2 alkylating agents that have po-
ent antileukemic activity, are myeloablative, and are
ew agents to the children undergoing transplantation
or hematologic malignancies. Early studies reported
ncouraging efﬁcacy in high-risk hematologic malig-
ancies. The major toxicity was early mucositis [21-
5]. The early clinical results were comparable to
hose in the TBI-based unrelated donor marrow
ransplantation experience [20].
A notable ﬁnding in this study was the slow rate of
eutrophil recovery and the high incidence of graft
ailure despite the high nucleated cell doses. The me-
ian precryopreservation TNC was 10  107/kg,
hich is similar to that of bone marrow transplanta-
ion and is well above the median of 3.5  107 TNCs
er kilogram generally used in pediatric recipients [6].
espite the high cell dose, the median time to neu-
rophil recovery was 31 days, which is similar to that
bserved in adults whose median cell dose was 2.0 
07 TNCs per kilogram [26]. This observation sug-
ests that there are variables other than nucleated and
D34 cell dose that account for the delayed recovery
igure 3. Maximum toxicity by organ system using the Bearman
oxicity scale (by day 42). Relative proportions of patients by grade
re shown. With the Bearman toxicity grading scale by day 42, the
aximum toxicity experienced in any organ system was 3 (9%)
rade 0, 2 (6%) grade I, 17 (53%) grade II, 5 (16%) grade III, and
(16%) grade IV. CNS indicates central nervous system; GI, gas-
rointestinal.nd poor engraftment. One variable may be the ade- m
B&MTuacy of immunosuppression achieved by this prepar-
tive regimen.
It is important to note that severe regimen-related
oxicity was observed infrequently. This suggests that
usulfan, melphalan, and ATG are well tolerated in
his young patient population. In this series, all pa-
ients had busulfan pharmacokinetics performed with
ose adjustment to achieve a steady-state exposure to
usulfan that was within the range sufﬁcient for en-
raftment of a variety of hematopoietic progenitor cell
ources [27,28]. Although long-term effects (eg, growth
nd development, endocrine, and fertility) have yet to
e determined, the paucity of severe toxicities early
fter transplantation suggests that increasing the level
f immunosuppression to enhance engraftment will be
olerated. Other reports suggest that the addition of
udarabine may enhance the engraftment of unrelated
BUs [29-31].
Although it is possible that limited numbers of
atients prevented any association between original
LA match and survival, an effect was observed with
igh-resolution HLA matching. As reported by Ru-
instein and colleagues [31,32], HLA matching is an
mportant predictor of survival. Although cell dose is
early always adequate in the setting of CBT in young
hildren, the need for more closely HLA-matched
onors argues for augmentation of the CBU inven-
ory. However, despite HLA mismatch, the incidence
f acute GVHD and chronic GVHD was similar to
hat observed after HLA-matched unrelated donor
one marrow transplantation.
In this small cohort, relapse and relapse-free sur-
ival were similar between patients in CR1 and those
n CR2 and beyond. On the basis of current results
ith improved outcome in front-line chemotherapy
nd the reasonable salvage with CBT in CR2, it is
easonable to consider CBT for infant acute leukemia
n CR1 for those who are at high risk for relapse and
ho would be unlikely to enter a second remission
hould relapse occur. The beneﬁt of CBT over a
olunteer unrelated stem cell donor is that the time to
onor identiﬁcation is short, thus allowing transplan-
ation immediately after reinduction/consolidation.
ong-term follow-up of this cohort would be neces-
ary to evaluate whether a non-TBI regimen is asso-
iated with a lower risk of late effects, including pul-
onary, dental, linear growth, and neurocognitive
evelopment. For the immediate future, however,
on–TBI-containing trials will need to be optimized
o improve engraftment and leukemia control after
BT.
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